This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
TESARO (TSRO) Q3 Earnings Beat, Revenues Miss, Shares Up
by Zacks Equity Research
TESARO (TSRO) beats estimates for earnings in the third quarter but misses the same on revenues. Zejula sales maintain momentum.
Clovis (CLVS) Q3 Earnings & Sales Lag, Rubraca Disappoints
by Zacks Equity Research
Clovis (CLVS) misses estimates in the third quarter for both earnings and sales and guides lower sales for only marketed drug, Rubraca in Q4. Shares decline.
Clovis Oncology (CLVS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of -6.88% and -24.46%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Clovis Oncology (CLVS) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis' Rubraca Gets Breakthrough Therapy Status for mCRPC
by Zacks Equity Research
Clovis' (CLVS) cancer drug, Rubraca, gets Breakthrough Therapy designation from the FDA for treating metastatic castration resistant prostate cancer with BRCA mutation.
Company News For Oct 3, 2018
by Zacks Equity Research
Companies In The News are: AMZN,CLVS,PEP,SFIX
Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Why Is Clovis (CLVS) Down 12.9% Since Last Earnings Report?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Clovis (CLVS) misses bottom-line estimates in the second quarter but beats on the top line. Rubraca sales increase.
TESARO (TSRO) Misses Earnings and Revenue Estimates in Q2
by Zacks Equity Research
TESARO (TSRO) misses estimates for both earnings and revenues in the second quarter but beats on revenues. Zejula sales increase.
Clovis Oncology (CLVS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of -40.58% and 1.63%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Clovis Gets EU Acceptance for Rubraca Label Expansion Filing
by Zacks Equity Research
Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.
Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
AstraZeneca/Merck's Lynparza Betters Survival in Phase III
by Zacks Equity Research
AstraZeneca (AZN) and Merck's (MRK) Lynparza significantly delays disease progression in a late-stage study evaluating it for the first-line treatment of advanced ovarian cancer.
Clovis Oncology (CLVS) Up 11.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Clovis Oncology (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clovis' Rubraca Gets Approval in Europe for Ovarian Cancer
by Zacks Equity Research
Clovis Oncology's (CLVS) PARP inhibitor, Rubraca, gets its first approval in Europe for the treatment of BRCA-mutant ovarian cancer in third- or later-line setting.
Clovis (CLVS) Q1 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Clovis (CLVS) witnesses wider year-over-year loss in the first quarter. However, the company's revenues beat estimates. Rubraca sales increase.
What's in Store for Horizon Pharma (HZNP) in Q1 Earnings?
by Zacks Equity Research
On Horizon Pharma's (HZNP) first-quarter 2018 earnings call, investors focus will be on the performance of its business units and key products.
Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy
by Zacks Equity Research
Clovis Oncology (CLVS) announces the FDA has granted label expansion of Rubraca to include maintenance treatment of ovarian cancer patients in second line setting, irrespective of BRCA mutation status. Shares up.
Clovis Oncology (CLVS) Surges: Stock Moves 5.9% Higher
by Zacks Equity Research
Clovis Oncology (CLVS) shares rose nearly 6% in the last trading session, amid huge volumes.
AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use
by Zacks Equity Research
AstraZeneca's (AZN) Bydureon gets FDA approval for expanded use in type II diabetes patients. Meanwhile, regulatory submissions for its leukemia candidate and Lynparza get acceptance in the United States and EU, respectively.
Why Is Clovis (CLVS) Down 9.3% Since its Last Earnings Report?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clovis Gets Positive CHMP Opinion for Ovarian Cancer Drug
by Zacks Equity Research
Clovis' (CLVS) ovarian cancer drug, Rubraca, gets positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Clovis Oncology (CLVS) Soars: Stock Adds 6.6% in Session
by Zacks Equity Research
Clovis Oncology (CLVS) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
Clovis (CLVS) Q4 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Clovis (CLVS) witnesses narrower year-over-year loss in the fourth quarter. However, the company's revenues miss estimates. Rubraca sales lower.